{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:51:53Z","timestamp":1793407913662,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ygyno.2023.07.020","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T05:19:51Z","timestamp":1692595191000},"page":"14-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma"],"prefix":"10.1016","volume":"177","author":[{"given":"Dimitrios","family":"Nasioudis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawar A.","family":"Latif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Cory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lainie","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Robert","family":"Giuntoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.07.020_bb0005","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/EDBK_350541","article-title":"Novel therapeutics in the treatment of uterine sarcoma","volume":"42","author":"Bose","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"12","key":"10.1016\/j.ygyno.2023.07.020_bb0010","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1634\/theoncologist.2018-0095","article-title":"Systemic treatment of metastatic\/recurrent uterine Leiomyosarcoma: a changing paradigm","volume":"23","author":"Arend","year":"2018","journal-title":"Oncologist."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0020","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0025","series-title":"AACR Project GENIE: Powering Precision Medicine Through An International Consortium, Cancer Discovery","author":"The AACR Project GENIE Consortium","year":"2017"},{"key":"10.1016\/j.ygyno.2023.07.020_bb0030","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0035","series-title":"OncoKB: A Precision Oncology Knowledge Base JCO Precision Oncology","first-page":"1","volume":"1","author":"Chakravarty","year":"2017"},{"issue":"8","key":"10.1016\/j.ygyno.2023.07.020_bb0040","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3390\/cancers14081934","article-title":"Role of homologous recombination repair (HRR) genes in uterine Leiomyosarcomas: a retrospective analysis","volume":"14","author":"Ciccarone","year":"2022","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0045","article-title":"Clinical outcome of Leiomyosarcomas with somatic alteration in homologous recombination pathway genes","volume":"4","author":"Rosenbaum","year":"2020","journal-title":"JCO Precis. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.07.020_bb0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tig.2023.02.009","article-title":"ATRX, a guardian of chromatin","volume":"39","author":"Aguilera","year":"2023","journal-title":"Trends Genet"},{"issue":"10","key":"10.1016\/j.ygyno.2023.07.020_bb0055","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3390\/cancers13102384","article-title":"ALT positivity in human cancers: prevalence and clinical insights","volume":"13","author":"MacKenzie","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"5","key":"10.1016\/j.ygyno.2023.07.020_bb0060","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.121","article-title":"Stalled replication forks within heterochromatin require ATRX for protection","volume":"7","author":"Huh","year":"2016","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.ygyno.2023.07.020_bb0065","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/hmg\/ddz250","article-title":"Functional cross talk between the Fanconi anemia and ATRX\/DAXX histone chaperone pathways promotes replication fork recovery","volume":"29","author":"Raghunandan","year":"2020","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.020_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.molcel.2018.05.014","article-title":"ATRX promotes DNA repair synthesis and sister chromatid exchange during homologous recombination","volume":"71","author":"Juh\u00e1sz","year":"2018","journal-title":"Mol. Cell"},{"issue":"15","key":"10.1016\/j.ygyno.2023.07.020_bb0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025182118","article-title":"Integrated mutational landscape analysis of uterine leiomyosarcomas","volume":"118","author":"Choi","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"14","key":"10.1016\/j.ygyno.2023.07.020_bb0080","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","article-title":"Genomic landscape of uterine sarcomas defined through prospective clinical sequencing","volume":"26","author":"Hensley","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.ygyno.2023.07.020_bb0085","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41379-022-01160-1","article-title":"Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors","volume":"35","author":"Momeni Boroujeni","year":"2022","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0090","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.ygyno.2023.07.020_bb0095","doi-asserted-by":"crossref","first-page":"9477","DOI":"10.7150\/thno.45763","article-title":"Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue sarcomas","volume":"10","author":"Li","year":"2020","journal-title":"Theranostics."},{"issue":"9","key":"10.1016\/j.ygyno.2023.07.020_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101147","article-title":"Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity","volume":"14","author":"Garbarino","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102971","article-title":"Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma","volume":"59","author":"George","year":"2020","journal-title":"EBioMedicine."},{"issue":"6219","key":"10.1016\/j.ygyno.2023.07.020_bb0110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.1257216","article-title":"Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors","volume":"347","author":"Flynn","year":"2015","journal-title":"Science."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0115","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2023.07.020_bb0120","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1158\/1541-7786.MCR-12-0575","article-title":"TDP1 and PARP1 deficiency are cytotoxic to rhabdomyosarcoma cells","volume":"11","author":"Fam","year":"2013","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.ygyno.2023.07.020_bb0125","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/gtc.12387","article-title":"Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor","volume":"21","author":"Yamasaki","year":"2016","journal-title":"Genes Cells"},{"issue":"1","key":"10.1016\/j.ygyno.2023.07.020_bb0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-017-0451-x","article-title":"Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas","volume":"10","author":"Laroche","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2023.07.020_bb0135","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S1470-2045(18)30438-8","article-title":"Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian sarcoma group","volume":"19","author":"Grignani","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0140","series-title":"Paper 18 - Phase II Multi-Center Trial of Trabectedin in Combination with Olaparib in Advanced Unresectable or Metastatic Sarcoma, In: Ctos 2022 Annual Meeting","author":"Siontis","year":"2022"},{"key":"10.1016\/j.ygyno.2023.07.020_bb0145","series-title":"CTOS 2022 Annual Meeting","article-title":"(P 134) PHASE II study of rucaparib and nivolumab in patients with leiomyosarcoma","author":"Movva","year":"2023"},{"issue":"10","key":"10.1016\/j.ygyno.2023.07.020_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140988","article-title":"Combinations of PARP inhibitors with Temozolomide drive PARP1 trapping and apoptosis in Ewing\u2019s sarcoma","volume":"10","author":"Gill","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.ygyno.2023.07.020_bb0155","doi-asserted-by":"crossref","first-page":"11506","DOI":"10.1200\/JCO.2021.39.15_suppl.11506","article-title":"NCI protocol 10250: a phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma","volume":"39","author":"Ingham","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2023.07.020_bb0160","doi-asserted-by":"crossref","first-page":"11509","DOI":"10.1200\/JCO.2022.40.16_suppl.11509","article-title":"Li Chen, et al correlative results from NCI protocol 10250: a phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma","volume":"40","author":"Bose","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2023.07.020_bb0165","article-title":"Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation","volume":"42","author":"Shammas","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"issue":"7","key":"10.1016\/j.ygyno.2023.07.020_bb0170","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1634\/theoncologist.2018-0448","article-title":"BRCA1\/2 functional loss defines a targetable subset in Leiomyosarcoma","volume":"24","author":"Seligson","year":"2019","journal-title":"Oncologist."},{"issue":"4","key":"10.1016\/j.ygyno.2023.07.020_bb0175","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2022.33.e55","article-title":"Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)","volume":"33","author":"Asano","year":"2022","journal-title":"J. Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582301421X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582301421X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:04:06Z","timestamp":1758773046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582301421X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":35,"alternative-id":["S009082582301421X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.07.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}